Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1709.35
as on 04:01PM, 04 Apr 2025
Sun Pharma Performance
Day's Low
Day's High
₹1,658.05Day's Price Range₹1,778.8552 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | + 8.02 % |
| 3 Month Return | -7.47 % |
| 1 Year Return | + 6.24 % |
| Market Stats | |
| Previous Close | ₹1,770.00 |
| Open | ₹1,778.85 |
| Volume | 53.45L |
| Upper Circuit | ₹1,947.00 |
| Lower Circuit | ₹1,593.00 |
| Market Cap | ₹4,10,130.32Cr |
Sun Pharma Fundamentals
P/E Ratio
35.84
PEG Ratio
3.38
Market Cap
₹4,10,130.32 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Mutual Fund Holdings of Sun Pharma
Sun Pharma Analyst Rating
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2051.84
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of20.04%
High
₹2450
Target
₹2051.84
Low
₹1475
Sun Pharma target price ₹2051.84, a slight upside of 20.04% compared to current price of ₹1709.35. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.10%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.33%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Sun Pharmaceutical Industries Ltd
Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025
Sun Pharmaceutical Industries Ltd reported a 10.4% revenue growth in FY24, driven by specialty drugs and a robust Indian market, despite potential tariff pressures on exports.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025
Sun Pharmaceutical Industries Ltd has entered into a merger agreement with Checkpoint Therapeutics, Inc. This merger aims to facilitate the launch of UNLOXCYT in the U.S. and support marketing authorization in Europe, enhancing the company's strategic position in the oncology market.Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025
Sun Pharmaceutical Industries Ltd is impacted by Lyndra Therapeutics ceasing operations due to funding issues and a broader decline in Indian pharma stocks amid tariff concerns.Sun Pharma Shares Surge with Increased Trading Volume - 21 Mar, 2025
On March 21, 2025, Sun Pharmaceutical Industries saw a 2.03% increase in share price to Rs 1786.50, driven by significant trading volume, reflecting strong investor interest and positive sentiment in the stock.Sun Pharma Plans Experimental Drug for Obesity - 20 Mar, 2025
Dilip Shanghvi, Managing Director of Sun Pharmaceuticals, announced plans to introduce an experimental drug, Utreglutide, for obesity and type 2 diabetes within four to five years.Sun Pharma Acquires Antibe Therapeutics for Growth - 19 Mar, 2025
Sun Pharmaceutical Industries has completed its acquisition of Antibe Therapeutics for CAD 4.5 million, aiming to expand its global footprint. Additionally, Sun Pharma is developing its GLP-1 receptor agonist, Utreglutide, with trials expected this year.Sun Pharma Gains on Acquisition and Profit Growth - 18 Mar, 2025
Sun Pharmaceuticals saw a 1.2% rise in shares, crossing key levels, following a 1.14% increase after its subsidiary's acquisition of Antibe Therapeutics. The company reported a 15.04% rise in Q3 net profit.Sun Pharma Issues Recall for Morphine Sulfate Tablets - 16 Mar, 2025
Sun Pharmaceutical Industries has recalled 9,840 bottles of Morphine Sulfate extended-release tablets due to Failed Dissolution Specifications, initiating a Class II nationwide recall on February 6, 2025.Sun Pharma Exhibits Signs of Recovery and Momentum - 15 Mar, 2025
Sun Pharmaceutical Industries is demonstrating early recovery signs, with price action above key moving averages and bullish momentum indicators. Short-term targets are set at ₹1,750, with mid-term potential reaching ₹1,860.Sun Pharma Shows Positive Momentum with Strong Indicators - 14 Mar, 2025
Sun Pharma's share price continues to rally, forming a morning star pattern and sustaining above its 20-day SMA. Rising volumes indicate buying activity, while the RSI suggests increasing strength. Analysts recommend buying, holding, and accumulating the stock, with an expected upside of 1,750-1,800 and a downside support at 1,600.Sun Pharma's Strategic Acquisition Boosts Specialty Portfolio - 13 Mar, 2025
Sun Pharmaceutical Industries is enhancing its specialty portfolio through the acquisition of Checkpoint Therapeutics for $350 million, gaining access to a promising skin cancer treatment. ICICI Securities has upgraded the stock to Buy, anticipating significant growth in the specialty segment. The acquisition aligns with Sun Pharma's focus on dermatology and oncology, despite initial earnings impact.Sun Pharma Acquires Checkpoint Therapeutics for $355 Million - 10 Mar, 2025
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million, adding the FDA-approved drug UNLOXCYT to its oncology portfolio. The deal is expected to close in Q2 2025.HSBC Lowers Target Price for Sun Pharma Shares - 06 Mar, 2025
HSBC maintains a Buy rating on Sun Pharma but reduces the target price to ₹2,000 from ₹2,280. The brokerage remains optimistic about growth in the specialty drug segment, particularly for Ilumya, while cautioning about the uncertain launch timeline for Leqselvi, which could impact long-term growth. Strong fundamentals support Sun Pharma's position in dermatology and immunology.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, SUNPHARMA stock has moved up by 8.0%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 135.9% return, outperforming this stock by 51.9%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 46.3% return, outperforming this stock by 40.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
Sun Pharma News
Pharma Stocks React to Trump's Potential Tariffs on Pharmaceuticals
Shares of large generic drug makers and contract manufacturing organisations such as Dr Reddys, Zydus Lifesciences Sun Pharma and Cipla closed the days trading 3-6% lower.05 Apr, 2025 05:30 AMSensex, Nifty Join Global Selloff Amid Trade War Fears
Tata Motors, Larsen & Toubro, Adani Ports, IndusInd Bank, Tech Mahindra, Reliance Industries, Sun Pharmaceutical, HCL Technologies, Tata Consultancy Services, Infosys, and NTPC, were the major laggards.04 Apr, 2025 04:10 PMPharma Companies Expected to See Up to 16% Sales Growth in FY25
Among the companies, Sun Pharma is likely to post the highest US sales growth of 12 per cent YoY, thanks to its strong specialty products portfolio. The report also notes that US sales across the covered companies are expected to grow 5 per cent YoY to USD 1.2 billion, supported by niche product launches and reduced price erosion. Sun Pharma is again expected to lead in US sales growth, driven by its strong specialty product performance.04 Apr, 2025 02:46 PMSun Pharma Financials
Sun Pharma Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (35.84x)
April 4, 2025
Industry (53.63x)
April 4, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.40%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bearish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,10,130.32 Cr | 61.91% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,45,552.44 Cr | 33.03% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,11,225.10 Cr | 35.84% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹39,355.67 Cr | 0.6% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹24,299.10 Cr | -3.79% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceutical Industries Ltd
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1709.35, Open: ₹1778.85, Previous Close: ₹1770, High: ₹1778.85, Low: ₹1658.05, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 53.45L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹410130.32Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1709.35. It is down -12.80% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1709.35. It is up 24.12% from its 52 Week Low price of ₹1377.2